The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCSRT.L Regulatory News (CSRT)

  • There is currently no data for CSRT

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Voke® (DEV200) update

3 Jan 2017 07:00

RNS Number : 1264T
Consort Medical PLC
03 January 2017
 

 

Consort Medical plc

 

03 January 2017

 

Voke® (DEV200) update

 

Consort Medical plc ("Consort Medical") (LSE: CSRT) today announces that Nicovations Limited ("Nicovations"), a wholly-owned subsidiary of British American Tobacco plc ("BAT"), has served termination notices for all Supply Agreements with Bespak Europe Limited ("Bespak"), a Consort Medical subsidiary, for Voke®. Termination is effective immediately.

 

· Nicovations has terminated all supply agreements with Bespak for Voke, an MHRA approved nicotine inhaler for harm reduction in smoking

· Bespak remains in a constructive dialogue with Kind Consumer and Nicovations over the future of the Voke programme

· Voke is one of 16 programmes in Bespak's growing development pipeline and Consort Medical's Board at this time does not believe that the Termination materially impacts their expectations for the Group's underlying trading performance for the current financial year

 

Nicovations has terminated the Supply Agreements on the basis of lack of commercial launch of Voke before 31 December 2016, which is a termination right provided for in the Supply Agreements that Nicovation has chosen to invoke.

 

Voke, one of 16 programmes in Bespak's development pipeline, was designed by Kind Consumer, a developer of innovative, medically-authorised products, for licensing into consumer and pharmaceutical markets. The distribution rights to the product were licensed by Kind Consumer to Nicovations and, in relation to this licence agreement, in 2011 Nicovations also entered into separate Supply Agreements with Bespak. The agreements cover the build, manufacturing and supply of the filled Voke devices and associated valves.

 

Bespak remains in a constructive dialogue with Kind Consumer and Nicovations over the future supply of the Voke nicotine inhaler which addresses a fast growing multi-billion dollar market.

 

With a robust financial position and a strong development pipeline, the board of directors of Consort Medical at this time does not believe that the termination of the Supply Agreements materially impacts their expectations for Consort Medical Group's underlying trading performance for the current financial year ending 30 April 2017.

 

Jonathan Glenn, Chief Executive Officer of Consort Medical, commented:

 

"Our recent interim financial results highlighted the underlying strength in Bespak and Aesica and the momentum emanating from the growing and diverse pipeline portfolio of significant development programmes. Therefore, while we are naturally disappointed in the loss of the Supply Agreements for Voke to Nicovations, we continue our dialogue with Kind Consumer and with Nicovations on the future of the programme and we remain highly confident in the robustness of the remainder of our business and our prospects for the future".

 

- Ends -

 

 

Enquiries:

 

Consort Medical

Tel: +44 1442 867920

Jonathan Glenn - Chief Executive Officer

FTI Consulting

Tel: +44 20 3727 1000

Ben Atwell / Simon Conway

 

 

Notes:

 

Market Abuse Regulations (MAR)

This announcement contains inside information.

 

About Consort Medical

 

Consort Medical plc is a leading, global, single source drug and delivery device company (CDMO). We are at the leading edge of innovation and we are committed to investing in patient, clinician and customer driven innovation to create new treatments, new markets and new opportunities.

 

Our businesses

 

Bespak is a global market leader in the manufacture of drug delivery devices for pharmaceutical partner companies, including respiratory, nasal, and injectable products, and the manufacture of devices for the point of care diagnostics market. www.bespak.com.

 

Aesica is a leading provider of finished dose and active pharmaceutical ingredient (API) development and manufacturing services to pharmaceutical partners. www.aesica-pharma.com.

 

We employ more than 2000 people globally of which 1400 are located in the UK. We have UK facilities in King's Lynn, Cambridge, Nelson, Milton Keynes, Cramlington, Queenborough and Hemel Hempstead, German facilities in Monheim and Zwickau and a facility in Pianezza, Italy. Consort Medical is a public company quoted on the premium list of the London Stock Exchange (LSE: CSRT). www.consortmedical.com.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCBTMBTMBIMTTR
Date   Source Headline
2nd Mar 20201:50 pmRNSTotal Voting Rights
20th Feb 20207:15 amRNSDespatch of formal compulsory acquisition notices
17th Feb 20204:24 pmRNSCompulsory acquisition of Consort Shares
6th Feb 20205:00 pmRNSNotice of Cancellation of Listing
6th Feb 20204:31 pmRNSDirector/PDMR Shareholding
6th Feb 20201:30 pmRNSHolding(s) in Company
5th Feb 20205:30 pmRNSConsort Medical
5th Feb 20204:51 pmRNSHolding(s) in Company
5th Feb 20204:00 pmRNSForm 8.3 - Consort Medical Plc
5th Feb 20203:15 pmBUSFORM 8.3 - CONSORT MEDICAL PLC
5th Feb 202011:42 amBUSForm 8.3 - CONSORT MEDICAL PLC
5th Feb 202011:32 amRNSForm 8.5 (EPT/RI)
5th Feb 20205:00 amGNWForm 8.5 (EPT/RI) - Consort Medical plc
4th Feb 20204:19 pmRNSOffer declared Wholly Unconditional
4th Feb 20203:38 pmBUSForm 8.3 - Consort Medical plc
4th Feb 20203:34 pmRNSForm 8.3 - Consort Medical plc
4th Feb 20203:25 pmBUSForm 8.3 - Consort Medical plc
4th Feb 20203:07 pmRNSForm 8.3 - Consort Medical Plc
4th Feb 20203:00 pmRNSForm 8.3 - Consort Medical Plc
4th Feb 202012:10 pmBUSForm 8.3 - Consort Medical Plc
4th Feb 202011:24 amRNSForm 8.5 (EPT/RI)
4th Feb 202011:08 amRNSForm 8.3 - CONSORT MEDICAL PLC
4th Feb 20209:20 amGNWForm 8.5 (EPT/RI) - Consort Medical plc
4th Feb 20207:25 amBUSForm 8.3 - Consort Medical Plc
3rd Feb 20204:24 pmBUSFORM 8.3 - CONSORT MEDICAL PLC AMENDMENT
3rd Feb 20201:37 pmBUSForm 8.3 - Consort Medical Plc
3rd Feb 202012:43 pmBUSForm 8.3 - CONSORT MEDICAL PLC
3rd Feb 202012:00 pmRNSAdditional Listing
3rd Feb 202010:53 amRNSForm 8.5 (EPT/RI)
3rd Feb 20209:58 amGNWForm 8.5 (EPT/RI) - Consort Medical plc
31st Jan 20205:28 pmRNSForm 8.3 - [Consort Medical plc]
31st Jan 20202:56 pmBUSForm 8.3 - CONSORT MEDICAL PLC
31st Jan 202010:57 amRNSForm 8.5 (EPT/RI)
31st Jan 20209:16 amGNWForm 8.5 (EPT/RI) - Consort Medical Plc
30th Jan 20203:25 pmBUSForm 8.3 - Consort Medical plc
30th Jan 20202:34 pmBUSForm 8.3 - CONSORT MEDICAL PLC
30th Jan 20201:30 pmBUSForm 8.3 - CONSORT MEDICAL PLC
30th Jan 20201:18 pmRNSForm 8.3 - Consort Medical plc
30th Jan 202010:34 amRNSForm 8.5 (EPT/RI)
30th Jan 20209:18 amRNSForm 8.3 - Consort Medical plc
30th Jan 20208:50 amGNWForm 8.5 (EPT/RI) - Consort Medical plc
29th Jan 20204:21 pmRNSHolding(s) in Company
29th Jan 20201:18 pmBUSForm 8.3 - Consort Medical Plc
29th Jan 202011:50 amRNSForm 8.3 - Consort Medical PLC
29th Jan 202011:19 amRNSForm 8.5 (EPT/RI)
29th Jan 202010:41 amRNSResponse to Recipharm Statement
29th Jan 20209:45 amRNSHolding(s) in Company
29th Jan 20207:00 amRNSNo Extension or Increase & Irish CCPC Clearance
28th Jan 20203:25 pmBUSForm 8.3 - Consort Medical plc
28th Jan 20201:59 pmRNSForm 8.3 - Consort Medical Plc

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.